Effectiveness of Native Vitamin D Therapy in Patients with Chronic Kidney Disease Stage 3 and Hypovitaminosis D in Colombia, South America.

Conclusion: Cholecalciferol with adjustment in its dose, and obtaining normal serum levels is an excellent therapeutic alternative for the treatment of patients with CKD stage 3, and hypovitaminosis D. In the group of patients with GFR close to 30 mL/min, or lower values (stage 4), and with the presence of secondary hyperparathyroidism, the use of active form of vitamin D (calcitriol, paricalcitol) is recommended as the first therapeutic alternative. PMID: 31827333 [PubMed]
Source: International Journal of Nephrology and Renovascular Disease - Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research

Related Links:

DISCUSSION: BIA should be interpreted with caution in patients with SHPT due to a loss of accuracy, which can compromise the interpretation of body composition. PMID: 32877488 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
CONCLUSIONS: Parathyroidectomy is an effective and safe intervention for the CKD-MBD in the elderly. PMID: 32891512 [PubMed - as supplied by publisher]
Source: Asian Journal of Surgery - Category: Surgery Authors: Tags: Asian J Surg Source Type: research
Renal osteodystrophy is a term that encompasses complications of bone metabolism associated with chronic kidney disease. Progressive loss of renal function raises parathyroid hormone levels (PTH) favor high bone turnover and skeletal manifestations. The clinic condition is a diagnostic and management challenge. A 37-year-old man, chronic renal, was referred by endocrinologist for evaluation of expansive gingiva lesion, present for 3 months, with a histopathological diagnosis suggestive of osteosarcoma.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: 20190721 Source Type: research
Authors: Xu W, Gong L, Lu J, Tang W Abstract Paricalcitol and cinacalcet have been recommended to reduce parathyroid hormone (PTH) levels for patients with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), and they are able to reduce the risk of hypercalcemia and hyperphosphatemia. However, to date, it has remained uncertain which is the better drug. The aim of the present meta-analysis was to evaluate the effects on PTH, calcium and phosphorus metabolism between the two drugs. The PubMed, the Cochrane Library and Embase databases were searched from inception to June 1, 2019 and eligible studie...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
It is controversial for the effect and safety between cinacalcet and other treatments in treating secondary hyperparathyroidism for patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD).
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
Authors: Dourado M, Cavalcanti F, Vilar L, Cantilino A Abstract CKD has a high prevalence worldwide, mainly due to its main etiologies-diabetes and hypertension. It has high cardiovascular morbidity and mortality, with traditional risk factors such as atherosclerosis, hypertension, diabetes, smoking, and left ventricular hypertrophy being common. Nontraditional cardiovascular risk factors, such as anemia, hyperparathyroidism, chronic inflammation, and microalbuminuria, are also well studied. Prolactin is a hormone not only related to lactation but also being considered a uremic toxin by some authors. It accumulates...
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
Primary hyperparathyroidism is associated with substantial morbidity, including osteoporosis, nephrolithiasis, and chronic kidney disease. Parathyroidectomy can prevent these sequelae but is poorly utilized in many practice settings.
Source: Surgery - Category: Surgery Authors: Source Type: research
ABSTRACTActive vitamin D analogs and calcimimetics are the main therapies used for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). Peripheral blood mononuclear cells (PBMCs) of 19 pediatric patients with CKD1 ‐5D and 6 healthy donors (HD) were differentiated into mature osteoclasts with RANK‐L and M‐CSF. The effects of single or combined treatment with active vitamin D (1.25‐D) and/or calcimimetic KP2326 were evaluated on osteoclastic differentiation and osteoclastic‐mediated bone resorption. A lthough 1.25‐D inhibited osteoclastic differentiation, a significant resi...
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Tags: Original Article Source Type: research
CONCLUSIONS: The only theory of SHPT that our data support is the tradeoff-in-the-nephron hypothesis. Other theories are not supported.
. PMID: 32567541 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Tags: Clin Nephrol Source Type: research
Chronic kidney disease (CKD) disrupts mineral homeostasis and its main underlying cause is secondary hyperparathyroidism (SHPT). We previously reported that calcium-sensing receptor (CaSR) mRNA and protein exp...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
More News: Calcium | Chronic Kidney Disease | Colombia Health | Hyperparathyroidism | Phosphorus | Study | Urology & Nephrology | Vitamin D | Vitamin D3 | Vitamins